A Clinical Study of Legend Biotech BCMA-chimeric Antigen Receptor Technology in Treating Relapsed/Refractory (R/R) Multiple Myeloma Patients

Trial Profile

A Clinical Study of Legend Biotech BCMA-chimeric Antigen Receptor Technology in Treating Relapsed/Refractory (R/R) Multiple Myeloma Patients

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs LCAR-B38M CAR-T cell therapy (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Proof of concept
  • Acronyms LEGEND-2
  • Sponsors Nanjing Legend Biotech
  • Most Recent Events

    • 05 Jul 2017 Status changed from active, no longer recruiting to recruiting.
    • 25 Jun 2017 Results (n=22; data cut off: 20 Feb,2017) presented at the 22nd Congress of the European Haematology Association.
    • 01 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top